Author

Martin C. Clasby

University of MichiganORCID 0000-0002-7852-1733Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:proteomics· 1 Organism:zebrafish· 1

Frequent Co-Authors

Allison C. FergusoniD· 1 shared Clayton J. HabigeriD· 1 shared David A. HanaueriD· 1 shared David Wu· 1 shared Douglas W. SelingeriD· 1 shared Ehab M. KhaliliD· 1 shared Hongyu Su· 1 shared Ilya KovalenkoiD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Allison C. FergusonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintDec 25, 2025

Phenotypic Screening Coupled with AI-Driven Target Deconvolution Identifies α-Terthienyl as a Dual DPP-IV/HSD17β13 Modulator with Efficacy in a Mouse Model of MASLD

Kathryn M. Hoegeman, Jesse W. Wotring, Reid M. Fursmidt…·Jonathan Z. Sexton

1 citation

mousebulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintSep 23, 2025

FDA-approved drug repurposing in zebrafish identifies thyroid hormone and other compounds as potential antithrombotics

Murat Yaman, Hongyu Su, Jacqueline K. Lee…·Jordan A. Shavit

This study uses zebrafish to screen FDA-approved drugs for antithrombotic effects, identifying thyroid hormone and others as potential treatments for VTE subtypes.

DOI 10.1101/2025.09.23.677920

zebrafishexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintMar 30, 2025

A gut-selective Axl Inhibitor Attenuates Intestinal Fibrosis in myofibroblast cell models and the Mouse S. Typhimurium Model in vivo

Yongjia Feng, Laura A. Johnson, Martin C. Clasby, Peter Higgins

This study tests a gut-selective Axl inhibitor, CCG264341, in vitro and in vivo models of intestinal fibrosis, finding it reduces fibrosis markers and Axl signaling.

DOI 10.1101/2025.03.30.646118

mouseproteomics

𝕏 PostBluesky